

World Journal of *Gastrointestinal Pharmacology and Therapeutics*

World J Gastrointest Pharmacol Ther 2020 November 8; 11(5): 79-122





ORIGINAL ARTICLE

Basic Study

- 79 Oral encapsulated transforming growth factor β 1 reduces endogenous levels: Effect on inflammatory bowel disease

Hammer L, Furtado S, Mathiowitz E, Auci DL

- 93 Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats

Berkopic Cesar L, Gojkovic S, Krezic I, Malekinusic D, Zizek H, Batelja Vuletic L, Petrovic A, Horvat Pavlov K, Drmic D, Kokot A, Vlajinac J, Seiwert S, Sikiric P

Retrospective Study

- 110 Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience

Yazawa T, Hori T, Yamamoto H, Harada H, Yamamoto M, Yamada M, Tani M, Sato A, Kamada Y, Tani R, Aoyama R, Sasaki Y, Zaima M

ABOUT COVER

Editorial board member of *World Journal of Gastrointestinal Pharmacology and Therapeutics*, Dr. Amir Abbasnezhad is a Distinguished Professor at the Lorestan University of Medical Sciences, Iran. Dr. Abbasnezhad completed his PhD in Nutrition at Ahvaz Jundishapoor University of Medical Sciences and his undergraduate studies at Urmia University. His research interests lie in the area of nutrition, gastroenterology, and complementary medicine; in addition, he has actively collaborated with researchers in several other medical disciplines, particularly in the fields of cancer and gastrointestinal disorders, such as inflammatory bowel diseases. In 2016, he became Deputy of Research of the Nutritional Health Research Center of the Lorestan University of Medical Sciences and won the Specialized Duty System Award from the Iran's National Elites Foundation. In 2017, 2018 and 2019, he consecutively won the Top Researcher Award from the Lorestan University of Medical Sciences. (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of the *World Journal of Gastrointestinal Pharmacology and Therapeutics* (WJGPT, *World J Gastrointest Pharmacol Ther*) is to provide scholars and readers from various fields of gastrointestinal pharmacology and therapeutics with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGPT mainly publishes articles reporting research results obtained in the field of gastrointestinal pharmacology and therapeutics and covering a wide range of topics including acid-related disorders, acute infectious gastrointestinal disease, chronic noninfectious inflammatory diseases, pharmacologic therapy for hepato-biliary diseases, functional gastrointestinal disorders, fundamentals of gastrointestinal pharmacology, etc.

INDEXING/ABSTRACTING

The WJGPT is now abstracted and indexed in PubMed, PubMed Central, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Jia-Hui Li; Production Department Director: Yun-Xiaojuan Wu; Editorial Office Director: Jia-Ping Yan.

NAME OF JOURNAL

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

ISSN 2150-5349 (online)

LAUNCH DATE

May 6, 2010

FREQUENCY

Irregular

EDITORS-IN-CHIEF

Emanuele Sinagra, Sin-Hyeog Im

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2150-5349/editorialboard.htm>

PUBLICATION DATE

November 8, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Basic Study

Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats

Lidija Berkopic Cesar, Slaven Gojkovic, Ivan Krezic, Dominik Malekinusic, Helena Zizek, Lovorka Batelja Vuletic, Andreja Petrovic, Katarina Horvat Pavlov, Domagoj Drmic, Antonio Kokot, Josipa Vlainic, Sven Seiwert, Predrag Sikiric

ORCID number: Lidija Berkopic Cesar 0000-0002-3801-5481; Slaven Gojkovic 0000-0003-4020-326X; Ivan Krezic 0000-0001-7994-5645; Dominik Malekinusic 0000-0001-6258-5647; Helena Zizek 0000-0001-9863-4164; Lovorka Batelja Vuletic 0000-0002-7785-2936; Andreja Petrovic 0000-0002-0883-2763; Katarina Horvat Pavlov 0000-0002-2661-7346; Domagoj Drmic 0000-0002-1081-7175; Antonio Kokot 0000-0002-4836-7536; Josipa Vlainic 0000-0002-3113-420X; Sven Seiwert 0000-0002-5894-419X; Predrag Sikiric 0000-0002-7952-2252.

Author contributions: Berkopic Cesar L was involved in conceptualization and methodology; Gojkovic S took part in the visualization and investigation; Krezic I took part in the visualization and investigation; Malekinusic D provided study resources; Zizek H was involved in visualization and investigation; Batelja Vuletic L took part in the formal analysis; Petrovic A was involved in formal analysis; Horvat Pavlov K took part in the formal analysis; Drmic D provided study resources; Kokot A took part in the validation; Vlainic J was involved in conceptualization and methodology; Seiwert S provided writing, review and editing of the

Lidija Berkopic Cesar, Slaven Gojkovic, Ivan Krezic, Dominik Malekinusic, Helena Zizek, Antonio Kokot, Predrag Sikiric, Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb 10 000, Croatia

Lovorka Batelja Vuletic, Andreja Petrovic, Katarina Horvat Pavlov, Sven Seiwert, Department of Pathology, School of Medicine, University of Zagreb, Zagreb 10000, Croatia

Josipa Vlainic, Institute Ruder Boskovic, Zagreb 10000, Croatia

Corresponding author: Predrag Sikiric, MD, PhD, Professor, Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, Zagreb 10000, Croatia. sikiric@mef.hr

Abstract**BACKGROUND**

After parietal peritoneum excision with an underlying superficial layer of muscle tissue in rats, there is failed vasculature, and finally, increased adhesion formation. We hypothesized that unlike nitric oxide (NO)-agents, L-NAME and/or L-arginine, the application of the stable gastric pentadecapeptide BPC 157 with its most recent vascular effects ("vascular recruitment") means attenuated bowel adhesion formation and NO- and malondialdehyde (MDA)-tissue values.

AIM

To focused on the bowel adhesion and the therapy with the BPC 157, its most and application of NO-agents.

METHODS

Along with defect creation, medication was (1) during surgery, once, at 1 min after defect creation as an abdominal bath (1 mL/rat), BPC 157 (10 µg/kg, 10 ng/kg, 1 mL/rat), an equivolume of saline, L-NAME (5 mg/kg), L-arginine (200 mg/kg) alone and/or combined. Alternatively, medication was (2) intraperitoneally once daily, first application at 30 min after surgery, last application 24 h before assessment at d 7 or d 14. As a postponed therapy to pre-existing adhesion (3), BPC 157 (10 µg/kg, 10 ng/kg intraperitoneally, 1 mL/rat) was given once daily since d 7.

RESULTS

manuscript; Sikiric P provided writing, review and editing of the manuscript.

Institutional animal care and use

committee statement: This research was approved by local Ethic Committee (case number 380-59-10106-17-100/290) and by Directorate of Veterinary (UP/I-322-01/15-01/22).

Conflict-of-interest statement: The authors state that they have no conflicts of interest.

Data sharing statement: The data that support the findings of this study are available on request from the corresponding author.

ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: Croatia

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): E

Received: February 13, 2020

The recovery effect of the BPC 157 regimens goes with the presence of abundant vascular vessels in and near the defect, which occurs rapidly. Lastly, also applied as post-treatment, BPC 157 creates attenuated adhesions, minimal or no adhesion. Contrarily, NO-agents have diverse initial and final effects: The initial weakening of blood vessel disappearance and finally, severe worsening of adhesions (L-NAME) *vs* the initial weakening of blood vessel disappearance and finally, attenuation of adhesions formation (L-arginine), which counteract each other response given together. Importantly, BPC 157 maintains its beneficial effect also when given with NO-agents (L-NAME + BC 157; L-arginine + BPC 157; L-NAME + L-arginine + BPC 157). Finally, with respect to the increased NO- and MDA-values-adhesion tissue formation relation, unlike diverse effect of the NO-agents, the BPC 157 application effect regularly combines decrease on the increased NO- and MDA- values and the beneficial outcome (less adhesion formation).

CONCLUSION

BPC 157 therapy can be suited for the realization of the peritoneal defect healing with minimal or no adhesion formation.

Key Words: Abdominal wall defect; Adhesions; BPC 157; Vascular recruitment; Nitric oxide-agents; Rats

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: After parietal peritoneum excision with an underlying superficial layer of muscle tissue in rats, there is failed vasculature, and finally, increased adhesion formation. Unlike nitric oxide-agents, L-NAME and/or L-arginine diverse effects, the application of the stable gastric pentadecapeptide BPC 157 with its most recent described vascular effects ("vascular recruitment") recovers abundant vascular vessel presentation in and close to the defect, which occurs rapidly. Finally, BPC 157 attenuated bowel adhesion formation and nitric oxide- and MDA-tissue values. Thus, BPC 157 therapy can be suited for the realization of the peritoneal defect healing with minimal or no adhesion formation.

Citation: Berkopic Cesar L, Gojkovic S, Krezic I, Malekinusic D, Zizek H, Batelja Vuletic L, Petrovic A, Horvat Pavlov K, Drmic D, Kokot A, Vlajic J, Seiwert S, Sikiric P. Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats. *World J Gastrointest Pharmacol Ther* 2020; 11(5): 93-109

URL: <https://www.wjgnet.com/2150-5349/full/v11/i5/93.htm>

DOI: <https://dx.doi.org/10.4292/wjgpt.v11.i5.93>

INTRODUCTION

We employed an excision of the parietal peritoneum with the underlying superficial layer of muscle tissue, and assessed the consequences thereof. There was a downhill course, from the very early events to massive bowel adhesion. However, recovery was achieved with the stable gastric pentadecapeptide BPC 157 and nitric oxide (NO) system involvement^[1-12]. This may be due to the rapid recovery of failed blood vessels after induction of the initial injury. Such therapy has had beneficial effects in previous studies on vascular occlusion^[13-19]. This recovery effect may be due to its effect on occluded vessels; it activated bypassing pathways, thereby counteracting occlusion consequences^[13-19]. This was described^[13-17] in the treatment of deep vein thrombosis and colitis ischemia/reperfusion, duodenal venous congestion and cecum perforation^[13-16], and bile duct ligation-induced liver cirrhosis and portal hypertension rat injuries^[17]. Recently, this recovery was also shown in the rescue of quite complex severe circumstances, *i.e.*, Pringle manoeuvre ischemia and reperfusion (portal triad temporary occlusion) as well as Budd-Chiari syndrome (induced by the suprahepatic occlusion of the inferior vena cava)^[18,19]. The cytoprotective impact of BPC 157 on the endothelium^[1-12] may have special importance. Namely, the peritoneal lining of the cavity serves as a conduit for blood vessels that are markedly disturbed by parietal

Peer-review started: February 13, 2020

First decision: March 26, 2020

Revised: August 13, 2020

Accepted: September 10, 2020

Article in press: September 10, 2020

Published online: November 8, 2020

P-Reviewer: Akyol C, Wang K

S-Editor: Zhang L

L-Editor: A

P-Editor: Li JH



peritoneum injury^[20]. This study assessed the normalisation of the level of malondialdehyde (MDA) and NO in tissue and the effect of the NO agents L-NAME and/or L-arginine, given alone and/or together, as confirmation^[13-19].

There, BPC 157 (GEPPPGKPADDAGLV, M.W. 1419, LD1 not achieved, implemented in inflammatory bowel disease trials and now multiple sclerosis^[1-12]) as a prototype of the more potent cytoprotective agent (*i.e.*, it also counteracts pre-existing lesions^[1-12]), may be an agent to counteract adhesion formation, as a therapy. As an anti-ulcer peptide, stable in human gastric juice, it is designed to be a novel mediator of Robert's cytoprotection^[1-12] (epithelium/endothelium protection^[1-12]). Likely, due to this effect (epithelium/endothelium protection^[1-12] as a shared class effect of cytoprotective agents), it is effective in the entire gastrointestinal tract^[1-12], and counteracts the bowel adhesion formation, which is induced by different procedures^[21-33]. Thereby, with an apparent vessel-adhesions related effect, BPC 157 corroborates all these vascular effects, and enhances vascular rescue after injury in particular^[13-19], by counteracting adhesion formation. Also, it interacts with the NO system in various species and models^[1-12], and counteracts the adverse effect of both L-NAME and L-arginine, given as individual agents or combined^[1-12].

The NO system is implicated in cytoprotection^[1-12] and adhesion formation^[34]. However, there has been no study of the effect of L-NAME (ulcerogenic) and/or L-arginine (beneficial)^[1-12] application on the immediate presentation of the blood vessels as a hallmark (vessel empty/disappeared; vessel filled/reappeared), during and after parietal peritoneum injury.

Therefore, it may be that formation of adhesion as an effect on the NO system suggests the beneficial effect related to the NO system. Thus, BPC 157, L-NAME and L-arginine were administered alone or in combination. The medication BPC 157 was applied either once, at 1 min after defect creation as an abdominal bath (1 mL/rat) to assess the initial post-injury course, blood vessel presentation, or to assess the subsequent course leading to adhesion formation intraperitoneally once daily, with the first application at 30 min after surgery and the last application 24 h before the assessment. Alternatively, from day 7, BPC 157 was given intraperitoneally once daily as a postponed therapy for a pre-existing adhesion. At these points in the injured tissue, levels of MDA and NO were assessed, and the results showed the NO levels and oxidative stress (MDA) were normalised in injured tissue.

MATERIALS AND METHODS

Animals

Male Albino Wistar rats, 200 g, were randomly assigned (7 rats per group) and used for the experiments, which were approved by the local ethics committee. The perforation procedure was performed in rats that had food and water *ad libitum* before the procedure and until the end of the experiment. The animal protocol was designed to minimise pain or discomfort to the animals. The animals were acclimatised to laboratory conditions (23 °C, 12 h/12 h light/dark, 50% humidity, *ad libitum* access to food and water) for 2 wk prior to experimentation. All animals were euthanised by a barbiturate overdose (intraperitoneal injection, 500 mg/kg thiopental sodium) prior to tissue collection.

Drugs

The pentadecapeptide Gly-Glu-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, M.W. 1419, called stable gastric pentadecapeptide BPC 157, part of the sequence of the human gastric juice protein BPC, freely soluble in water and 0.9% NaCl at pH 7.0 (Diagen, Ljubljana, Slovenia), prepared as described previously^[1-12]. The peptide had 99% purity by high-pressure liquid chromatography, with the 1-des-Gly peptide as a biologically inactive impurity^[1-12]. L-NAME and L-arginine were commercially purchased (Sigma, United States).

Procedure and adhesion assessment

Under deep anaesthesia (thiopental (Rotexmedica, Germany) 40 mg/kg, diazepam (Apaurin, Krka, Slovenia; 10 mg/kg), excision of the parietal peritoneum (1 cm × 2 cm, 2 cm right of the median, 3 cm laparotomy) with an underlying superficial layer of muscle tissue was performed in rats. BPC 157 (10 µg/kg, 10 ng/kg, 1 mL/rat), or an equivalent volume of 0.9% NaCl were applied, with L-NAME (5 mg/kg) or L-arginine (200 mg/kg) given alone or in combination with BPC 157 at both concentrations. The medication was applied either once at 1 min after defect creation as an abdominal bath

(1 mL/rat), or intraperitoneally once daily, with the first application at 30 min after surgery and the last application 24 h before the assessment. Alternatively, starting from d 7, BPC 157 (10 µg/kg, 10 ng/kg intraperitoneally, 1 mL/rat) was given once daily as a postponed therapy for a pre-existing adhesion. Immediately after defect creation, using a USB microscope camera (Veho discovery VMS-004D-400x USB microscope; Veho®, United Kingdom), we recorded the presentation of blood vessels, *i.e.* augmentation/reduction^[13-19] (emptied/disappeared; refilled/reappeared) and assessed at the end of the next 10-min period as total% of vascular vessels presentation in and close to the defect concerning the point immediately before therapy. Also, using a USB microscope camera (Veho discovery VMS-004D-400x USB microscope; Veho®, United Kingdom) at d 7 or d 14, adhesions were scored using Mazuji's classification [no adhesion (score 0); very small, irregular adhesion (score 1); easily separable medium intensity adhesion (score 2); intense, not easily separable regular adhesion (score 3); very intense, not easily separable, homogenous adhesion]^[35].

Immediately after culling the animals, tissue specimens were fixed in buffered formalin (pH 7.4), for 24 h, dehydrated and embedded in paraffin wax. The samples were stained with haematoxylin-eosin. Tissue injury was evaluated microscopically by a blinded examiner.

Oxidative stress in adhesion tissue

At 7 d or 14 d post-injury, oxidative stress in the tissue samples (1 cm² around the defect) was assessed by quantifying thiobarbituric acid reactivity as MDA equivalents. Trichloroacetic acid was added to homogenise the tissue samples, which were then centrifuged (3000 rpm, 5 min), and the supernatant was collected. Thereafter, 1% thiobarbituric acid was added, and the samples were boiled (95 °C, 60 min). The tubes were kept on ice for 10 min, and the absorbance was determined at the wavelengths of 532 and 570 nm. The concentration of MDA was read from a standard calibration curve plotted using 1,1,3,3'-tetra-ethoxy propane. The extent of lipid peroxidation was expressed as MDA using a molar extinction coefficient for MDA of 1.56×10^5 mol/L/cm. The results are expressed in nmol/mg of protein^[13-19].

Nitric oxide determination in adhesion tissue

At 7 d or 14 d post-injury, we determined the NO levels in cecum tissue samples using the Griess reaction (Griess Reagent System, Promega, United States). Sulphanilamide was then incubated with the homogenised tissue, and then, N-1-naphthyl ethylenediamine dihydrochloride was added. The Griess reaction is based on a diazotisation reaction in which acidified nitrite reacts with diazonium ions and, in a further step, are coupled to N-1-naphthyl ethylenediamine dihydrochloride, forming a chromophoric azo derivate. The absorbance was measured at 540 nm using a sodium nitrite solution as the standard. NO levels are reported in µmol/mg protein. The protein concentrations were determined using a commercial kit (BioRad Protein DR Assay Reagent Kit, United States)^[13-19].

Statistical analyses

Statistical analysis was performed by parametric one-way ANOVA with the post-hoc Newman-Keuls test and non-parametric Kruskal-Wallis and subsequent Mann-Whitney *U*-tests to compare between groups. The values are represented as mean ± SD and minimum/median/maximum. Results with $P < 0.05$ were considered significant. The statistical methods of this study were reviewed by Bozo Radic, MD, PhD at Clinical Hospital Dubrava.

RESULTS

In this study, the focus was on the possible therapeutic effect of the application of the stable gastric pentadecapeptide BPC 157, and NO agents, *i.e.* L-NAME and L-arginine, after the creation of a defect by the excision of the parietal peritoneum with an underlying superficial layer of muscle tissue in rats. Therefore, this study reveals the formation of adhesions which could extensively occupy and obstruct the abdominal wall and intestine and pelvic organs (Figures 1-5 with respect to the initial defect creation, and the early presentation of blood vessels in and close to the peritoneal defect (Figures 6 and 7). Support was obtained from the presentation of MDA- and NO tissue levels in adhesion tissues (Figure 8).




Figure 1 At 7 d (7) or 14 d (14) post-injury, we assessed the adhesion score (0-4), min/med/max. Medication (/kg), was BPC 157 [10 μg (μ) or 10 ng (n)] (b - 1 mL bath/rat at abdominal cavity, B - once daily intraperitoneally, first application at 30 min following surgery, last 24 h before sacrifice; B once daily intraperitoneally, first application at day 7 following surgery, last 24 h before sacrifice) or saline(controls)(C) (bath equal volume, or once daily intraperitoneally (since not different results are shown together)). ^a*P* < 0.05 at least vs control.

Adhesions

Controls: The induction of particular defect resulted in the formation of a large adhesion, which occupied and obstructed the abdominal wall, intestine and pelvic organs, as observed on d 7 and d 14 in all controls (Figures 1-5).

BPC 157: On d 7 and 14, after treatment with BPC 157, the degree of adhesion was minimal or absent. To emphasise the conclusive point (less or no adhesion formation), medication (/kg), BPC 157 (10 μg or 10 ng) was applied once as a 1 mL bath/rat in the abdominal cavity immediately after the creation of the defect, or once daily intraperitoneally, with the first application at 30 min after surgery and the last 24 h before culling. The final application was given once daily intraperitoneally, with the first application on d 7 following surgery and the last 24 h before culling (Figure 1, Figure 4, and Figure 5).

NO agents: The application of L-NAME resulted in severe worsening. On the contrary, the L-arginine caused the attenuation of adhesion formation. When used together, L-NAME and L-arginine antagonised each other, leading to adhesion formation similar to control animals (Figure 2).

BPC 157 and NO agents: Together, all these treatments (L-NAME + BPC 157, L-arginine + BPC 157, L-arginine + L-NAME + BPC 157) produced a benefit similarly to the application of BPC 157 alone (Figure 2).

Microscopic images (Figure 5) are provided along with the gross presentation. After the first week, controls presented oedematous granulation tissue, covering large areas of the serosa, whereas in BPC 157-treated rats, far smaller areas were covered with denser and more mature granulation tissue with vessels appearing to be more mature and better formed. After two weeks, large areas of still poorly organised granulation tissue invading the bowel and abdominal wall were obvious in control animals. In BPC 157-treated rats, a young connective tissue scar had formed in small areas, with poor invasion into the bowel serosa/subserosa leading to very limited and non-strangulating adhesions.

Vascular presentation

Controls: Along with defect creation, since the blood vessels quickly became empty, they rapidly disappeared close to the defect.

BPC 157: Recruitment of blood vessels appeared after or with BPC 157 treatment as an abundant vascular presentation within and close to the defect, which occurred rapidly.

NO agents: The application of L-NAME and L-arginine led to the slowing of blood vessel disappearance. When used together, L-NAME and L-arginine antagonised each other, showing similar vessel presentation as with the application of the saline in control animals.




Figure 2 At 7 d or 14 d post-injury, we assessed the adhesion score (0-4), min/med/max. Medication (/kg, 1 mL bath/rat) at abdominal cavity was BPC 157 (10 µg) (B), L-arginine (A) (100 mg), L-NAME (5 mg) alone or in combinations (L-NAME + L-arginine (NA), L-arginine + BPC 157 (AB), L-NAME + BPC 157 (NB), L-arginine + L-NAME + BPC 157 (ANB) or saline bath equal volume (controls) (C). ^a $P < 0.05$ at least vs control; BPC 10 ng presented adhesion score 1/1/1 with L-arginine (L-arginine + BPC 157); Score 1/1/1 with L-NAME (L-NAME + BPC 157); Score 1/1/1 with L-arginine and L-NAME (L-arginine + L-NAME + BPC 157), ^a $P < 0.05$ at least vs control.

BPC 157 and NO agents: Given together, these treatments (L-NAME + BPC 157, L-arginine + BPC 157, L-arginine + L-NAME + BPC 157) produced a benefit in much the same way as the application of BPC 157 alone.

NO/oxidative stress

Controls: Along with adhesion formation, increased values appeared at day 7, while on day 14 the values, particularly NO were not as high.

BPC 157: With BPC 157 treatment, the values of NO and MDA appeared to be normalised (decreased) at both time points.

NO agents: The application of L-NAME reduced NO values, and L-arginine increased NO values at day 7 and d 14. When given together, L-NAME and L-arginine antagonised each other. Interestingly, compared with the controls at day 7 and day 14, both L-NAME and L-arginine increased MDA values, and when given together, L-NAME and L-arginine antagonised each other.

BPC 157 and NO agents: Given together, all of these treatments (L-NAME + BPC 157, L-arginine + BPC 157, L-arginine + L-NAME + BPC 157) produced a counteracting effect on both increased NO and MD levels, much like the application of BPC 157 alone.

Thus, in rats with the parietal peritoneum and adjacent muscle removed, we




Figure 3 Adhesion formation (Control rats). Illustrative presentation of adhesion formation leading to subileus presentation at day 14 post injury.




Figure 4 Adhesion formation. BPC 157 rats. Illustrative presentation of the abdominal wall healing without adhesion formation at d 14 post injury.

demonstrated the particular combination of early to final response, which was affected by the application of the stable gastric pentadecapeptide BPC 157, L-arginine and L-NAME, administered alone or together. Of note, only with the BPC 157 application was a beneficial outcome observed, *i.e.* less adhesion formation and suppressed NO and MDA values.

DISCUSSION

In this study, we performed an excision of the parietal peritoneum with the underlying superficial layer of muscle tissue, and assessed the downhill consequences thereof with the rapid recovery of the failed blood vessels after induction of the initial injury. Recovery with the stable gastric pentadecapeptide BPC 157 involved the NO system^[11-12], as shown with the related effects of L-arginine and/or L-NAME.

This study on abdominal wall injury has basic relationships, such as vascular failure (vessels, one empty, “disappear”) at a very early post-injury time point, followed by a failure outcome (*i.e.*, the formation of extensive adhesions). MDA values and NO levels increased after the initial abdominal wall defect was made^[36,37], and increase during subsequent adhesion formation^[36,37]. On the contrary, the possible recovery effect is that the filled vessels “reappeared” and adhesion formation was attenuated. Suppression of NO and MDA levels matched with the beneficial outcome (less adhesion formation. Only BPC 157 therapy in the damaged abdominal wall led to this combined beneficial effect. The very rapid activation of the blood vessels in the initial defect likely circumvented the subsequent negative chain of events and resulted in the resolution of adhesion and obstruction. Similar effectiveness was observed after




Figure 5 Histological assessment after 7 d (upper) and 14 d (low), in rats subjected to the excision of the parietal peritoneum with underlying superficial layer of muscle tissue, controls [upper left (7 d), low left (14 d)] and BPC 157-treated rats [upper right (7 d), low right (14 d)]. 7 d. Upper, left, controls. Edematous, relatively poorly formed granulation tissue, covering large areas of serosa. Upper, right, BPC 157. By far smaller areas covered with more dense and mature granulation tissue with vessels appearing more mature and better formed. 14 d. Low, left, controls. After two weeks large areas of still poorly organized granulation tissue invading the bowel and abdominal wall. Low, right, BPC 157. Young connective tissue scar is formed in smaller areas, with poor invasion into the bowel serosa/subserosa leading to very limited and non-strangulating adhesions. HE stain, objective $\times 10$.

postponing therapy, as this counteracting effect occurred even with pre-existing adhesions (adhesion reduction from day 7 to d 14).

The effect of BPC 157 is quite persistent, since BPC 157 + L-NAME, BPC 157 + L-arginine and BPC 157 + L-NAME + L-arginine rats showed similar outcomes as BPC 157-rats. Thus, this counteraction occurred when challenged with nitric oxide synthases (NOS) blockade (L-NAME; less vessel presentation within and close to the defect, more adhesions and higher NO and MDA values) as well as NOS overstimulation (L-arginine; less vessel presentation within and close to the defect, fewer adhesions but higher NO and MDA values). Thus, the NO system was immobilised when L-NAME and L-arginine counteracted each other's effect. In these rats, which exhibited a disease course similar to the controls, in any circumstance, early or late, additional BPC 157 co-application (L-NAME + L-arginine + BPC 157) re-established the counteraction, as did BPC 157 application (BPC 157 + L-NAME-, BPC 157 + L-arginine-, BPC 157 + L-NAME + L-arginine-rats \approx BPC 157-rats). Important for the establishing BPC 157-NO relationships (for review see, see^[1-12]), L-NAME (NOS blockade) *vs* L-arginine (NOS over-stimulation) *vs* the combination (NO system immobilisation) were able to fully highlight the particularities of the NO system^[1-12]. Thus, with supportive evidence, it is conceivable that BPC 157 therapy mitigates the disturbances caused by parietal peritoneum and adjacent muscle removal and NO agent-induced effects (thereby, particular relations BPC 157 with the healing and NO system). It appears much like vessel recruitment to bypass occlusion and re-establish blood flow in previous occlusion- and ischemia/reperfusion studies^[13-19]. BPC 157 therapy may be useful as a combined therapeutic (cytoprotective), while NO agents, *i.e.*, L-NAME and/or L-arginine, are used as an additional control.

Finally, the suggested vessels/adhesions/BPC 157/NO system relationship supports the evidence that the stable gastric pentadecapeptide BPC 157 counteracts bowel adhesion formation related to different procedures^[21-28]. Likewise, this may resolve adhesions as an aberrant peritoneal wound healing process^[38]. Namely, BPC 157 accelerates the healing of various wounds (*i.e.*, skin^[39-42], muscle^[43-46], tendon^[47-49], ligament^[50], bone^[51]; ulcers in the entire gastrointestinal tract^[14-16,27,28,52-54], corneal ulcers^[55], gastrointestinal fistulas^[21-25,56]). Consistently, it appears to synchronise healing in various tissues. Also, once the peritoneum is damaged, the coagulation cascade is set in motion^[57]; BPC 157 counteracts the whole Virchow triad^[13], venous^[13,18,19] and arterial thrombosis^[18,19,58] and attenuates prolonged bleeding and thrombocytopenia after amputation and anticoagulant use^[13,59,60]. Therefore, BPC 157 is likely to interfere when two damaged peritoneal surfaces come into contact with each other. Therefore,




Figure 6 Total % of vascular presentation in (dash) and close to (dash dot) the defect. White square indicates the values immediately before therapy and full oval the values at the end of the next 10 min. Medication (/kg, 1 mL bath/rat) at abdominal cavity was BPC 157 (10 μ g) (B), L-arginine (A) (100 mg), L-NAME (5 mg) alone or in combinations (L-NAME + L-arginine (NA), L-arginine + BPC 157 (AB), L-NAME + BPC 157 (NB), L-arginine + L-NAME + BPC 157 (ANB) or saline bath equal volume (controls) (C). ^a $P < 0.05$ at least vs control; BPC 10 ng presented values 20 ± 8 (in) and 35 ± 8 (close to) with L-arginine (L-arginine + BPC 157); 25 ± 9 (in) and 45 ± 8 (close to) with L-NAME (L-NAME + BPC 157); 20 ± 7 (in) and 55 ± 15 with L-arginine and L-NAME (L-arginine + L-NAME + BPC 157), ^a $P < 0.05$ at least vs control.

by counteracting adhesion formation and reversing existing adhesions, BPC 157 is likely to interfere with and reverse the healing that would result in fusion to form a connection, *e.g.*, an adhesion. Likely, this beneficial effect could be related to the temporary role of fibrin in healing without adhesions that must be degraded by the fibrinolytic system for the restoration of normal tissue structure and function^[36,37].

Interestingly, when given with aspirin, clopidogrel or cilostazol, BPC 157 largely rescues thrombocyte function in rats and does not affect coagulation factors^[61]. Additionally, these BPC 157 assets, in particular abundant vascular presentation within and close to the defect as an extension of the original cytoprotective endothelium protection effect^[1-12], should be viewed with the stronger angiogenesis effect than the standard anti-ulcer agents^[62], along with increased expression of vascular endothelial growth factor (VEGF), and subsequent pathways^[3,13,63-67].

In particular, BPC 157 increases the expression and internalisation of VEGFR2, the activation of the VEGFR2-Akt-eNOS signalling pathway without the need for other known ligands or shear stress^[63], and heals corneal ulcer and lesions while maintaining corneal transparency^[55,68], much like it heals lesions in the entire gastrointestinal tract^[14-16,27,28,52-54] and other tissues, gastrointestinal fistulas in particular^[21-25,56]. BPC 157 also counteracts tumour cachexia and muscle wasting, characterised by increased pro-inflammatory/pro-cachectic cytokines such as interleukin-6 and tumour necrosis factor- α , and significantly corrects deranged muscle proliferation and myogenesis through changes in the expression of FoxO3a, p-AKT, p-mTOR and P-GSK-3 β (mitigating cancer cachexia)^[3]. Also, BPC 157 actually counteracts the tumour-promoting effect of VEGF^[69].

Finally, as an additional clue, a very recent investigation showed that BPC 157 is a stabiliser of cellular junctions, leading to significantly mitigated indomethacin-induced leaky gut syndrome, *via* increased expression of the tight junction protein ZO-1 (Zonula occludens-1) as well as improved transepithelial resistance^[70]. Likewise, the mRNAs of inflammatory mediators [iNOS, interleukin-6, IFN- γ (Interferon gamma) and tumour necrosis factor- α] were inhibited, along with increased expression of HSP (Heat shock proteins) 70 and HSP 90, and antioxidant proteins such as HO-1, NQO-1, glutathione reductase, glutathione peroxidase 2 and GST-pi^[70].

CONCLUSION

In summary, adhesion-related obstruction accounts for a considerable number of emergency surgical presentations, and continued research for preventing adhesions is more than desirable^[71,72]. Therefore, BPC 157 therapy, establishing the vessels/adhesions/BPC 157/NO system relationship, may be suitable for peritoneal defect healing with minimal or no adhesion formation. Finally, BPC 157^[1-12], with lethal dose not achieved, has been implemented in inflammatory bowel disease trials, with a particular effect on vessel presentation and the ability to counteract the harmful effects of NO agents, *i.e.* free radical formation and elevated NO^[1-12]. BPC 157 should be further assessed as a therapy to avoid adhesion formation.




Figure 7 Early vascular presentation in and close to defect, before and immediately after therapy application. A: Control rats. Illustrative presentation of the vessels in and close to the defect immediately before therapy (left), and immediately after therapy application at the abdominal cavity, under saline solution immersion (right). No particular vessel recruitment; B: BPC 157 rat. Illustrative presentation of the vessels in and close to the defect immediately before therapy (left), and immediately after therapy application at the abdominal cavity, under BPC 157 solution immersion (right). Particular vessel recruitment in and close to the defect.




Figure 8 Support was obtained from the presentation of MDA- and NO tissue levels in adhesion tissues. A: At 7 d post-injury, we determined nitric oxide (NO) in adhesion tissue samples using the Griess reaction. Medication (/kg, 10 mL/2 min bath/rat) at abdominal cavity was BPC 157 (10 μ g) (B), L-arginine (A) (100 mg), L-NAME (5 mg) alone or in combinations L-NAME + L-arginine (NA), L-arginine + BPC 157 (AB), L-NAME + BPC 157 (NB), L-arginine + L-NAME + BPC 157 (ANB) or saline bath equal volume (controls) (C). ^a $P < 0.05$ at least vs control; B: At 14 d post-injury, we determined NO in adhesion tissue samples using the Griess reaction. Medication (/kg, 10 mL/2 min bath/rat) at abdominal cavity was BPC 157 (10 μ g) (B), L-arginine (A) (100 mg), L-NAME (5 mg) alone or in combinations L-NAME + L-arginine (NA), L-arginine + BPC 157 (AB), L-NAME + BPC 157 (NB), L-arginine + L-NAME + BPC 157 (ANB) or saline bath equal volume (controls) (C). ^a $P < 0.05$ at least vs control; C: At 7 d post-injury, we determined oxidative stress in adhesion tissue samples was assessed by quantifying thiobarbituric acid reactivity as malondialdehyde equivalents. Medication (/kg, 1 mL bath/rat) at abdominal cavity was BPC 157 (10 μ g) (B), L-arginine (A) (100 mg), L-NAME (5 mg) alone or in combinations L-NAME + L-arginine (NA), L-arginine + BPC 157 (AB), L-NAME + BPC 157 (NB), L-arginine + L-NAME + BPC 157 (ANB) or saline bath equal volume (controls) (C). ^a $P < 0.05$ at least vs control; and D: At 14 d post-injury, we determined oxidative stress in adhesion tissue samples was assessed by quantifying thiobarbituric acid reactivity as malondialdehyde equivalents. Medication (/kg, 1 bath/rat) at abdominal cavity was BPC 157 (10 μ g) (B), L-arginine (A) (100 mg), L-NAME (5 mg) alone or in combinations L-NAME + L-arginine (NA), L-arginine + BPC 157 (AB), L-NAME + BPC 157 (NB), L-arginine + L-NAME + BPC 157 (ANB) or saline bath equal volume (controls) (C). ^a $P < 0.05$ at least vs control.

ARTICLE HIGHLIGHTS

Research background

The excise parietal peritoneum with the underlying superficial layer of muscle tissue, since the very early events to the huge bowel adhesion, may represent a model relevant to adhesion-related obstruction and a considerable number of emergency surgical presentation. The downhill course can be counteracted with the recovery by the stable gastric pentadecapeptide BPC 157 and NO-system involvement. This may be the rapid recovery of the failed blood vessels after the initial injury induction. The previous studies of vascular occlusion reveal its particular effect on the occluded vessels, and bypassing of the occlusion, in the therapy of the deep vein thrombosis and colitis ischemia/reperfusion, duodenal venous congestion and cecum perforation, bile duct ligation-induced liver cirrhosis and portal hypertension rat injuries, Pringle maneuver ischemia and reperfusion (portal triad temporary occlusion) as well as Budd-Chiari syndrome (induced by the suprahepatic occlusion of the inferior caval vein). Also, the BPC 157 cytoprotective endothelium impact can have special importance. Namely, the peritoneal lining of the cavity serves as a conduit for the blood vessels that should be markedly disturbed by parietal peritoneum injury. Thus, we considered that BPC 157 therapy is suited for the realization of the peritoneal defect healing with minimal or no adhesion formation.

Research motivation

Adhesion-related obstruction accounts for a considerable number of emergency

surgical presentation, and thereby, whatever mechanisms, the continued research for preventing is more than desirable. Therefore, BPC 157 therapy, establishing vessels-adhesions-BPC 157-NO-system relation, can be suited for the realization of the peritoneal defect healing with minimal or no adhesion formation.

Research objectives

The focus was on the possible therapeutic effect of the application of the stable gastric pentadecapeptide BPC 157, and NO-agents, L-NAME, and L-arginine after the creation of a particular defect by excision of parietal peritoneum with an underlying superficial layer of muscle tissue in rats. The revealing focus was on the formation of the adhesion, which could extensively occupy and obstruct the abdominal wall and intestine and pelvic organs, with respect to the initial defect creation, and the early blood vessels presentation in and close to the peritoneal defect. The support was the presentation of the MDA- and NO-tissue level in adhesion tissues.

Research methods

In the rats with the excised parietal peritoneum with the underlying superficial layer of muscle tissue, we suggest that this formation of adhesion would be an effect on the NO-system and that the BPC 157 beneficial effect would be an effect related to the NO-system.

The medication was BPC 157, L-NAME, L-arginine administered alone or in combinations. The medication was applied either once, at 1 min after defect creation as an abdominal bath (1 mL /rat) to perceive the initial post-injury course, blood vessel presentation (assessed by USB microscope camera, the blood vessels presentation augmentation/reduction to perceive subsequent course leading to the adhesion formation). Application was intraperitoneally once daily, first application at 30 min after surgery, last application 24 h before assessment. Alternatively, from day 7, BPC 157 was given intraperitoneally once daily as a postponed therapy to pre-existing adhesion. At these points in the injured tissue (gross and microscopy assessment), levels of MDA and NO were also assessed.

Research results

After parietal peritoneum excision with an underlying superficial layer of muscle tissue in rats, there is failed vasculature, and finally, increased adhesion formation. NO-agents, L-NAME and/or L-arginine have diverse effects, the initial weakening of blood vessel disappearance and finally, severe worsening of adhesions (L-NAME) *vs* the initial weakening of blood vessel disappearance and finally, attenuation of adhesions formation (L-arginine), which counteract each other response given together. The application of the stable gastric pentadecapeptide BPC 157 with its most recent described vascular effects ("vascular recruitment") recovers abundant vascular vessel presentation in and close to the defect, which occurs rapidly. Finally, BPC 157 attenuated bowel adhesion formation and NO- and MDA-tissue values.

Research conclusions

BPC 157 therapy can be suited for the realization of the peritoneal defect healing with minimal or no adhesion formation. In practical BPC 157 therapy realization, establishing vessels-adhesions-BPC 157-NO-system relation may be important. Finally, BPC 157, with LD1 not achieved, implemented in inflammatory bowel disease trials, with a particular effect on vessel presentation and counteracting effect on NO-agents harmful effect, free radical formation, and NO-values normalization, should be the practical hallmark of the further therapy to avoid adhesion formation.

Research perspectives

This study of abdominal wall injury has basic relationships, such as more vascular failure (vessels, since empty "disappear") at a very early post-injury period, as the more failed outcome (*i.e.*, the huge adhesion formation). MDA values and NO-levels increased at the initial abdominal wall defect, and thus increase during subsequent adhesions. On the contrary, the possible recovering effect is that the filled vessels "reappear"; adhesion formation attenuated. Decreasing of the increased NO- and MDA- values match with the beneficial outcome (less adhesion formation). Only the BPC 157 therapy in the damaged abdominal wall healing fulfils this combined beneficial effect. The very rapid activation of the blood vessels in the initial defect likely circumvents subsequent negative chain of events and results in the resolution of the adhesion and obstruction, decreasing of the increased NO- and MDA values match with the beneficial outcome (less adhesion formation).

REFERENCES

- 1 **Sikiric P**, Hahm KB, Blagaic AB, Tvrdeic A, Pavlov KH, Petrovic A, Kokot A, Gojkovic S, Krezic I, Drmic D, Rucman R, Seiwerth S. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. *Gut Liver* 2020; **14**: 153-167 [PMID: [31158953](#) DOI: [10.5009/gnl18490](#)]
- 2 **Seiwerth S**, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, Drmic D, Stupnisek M, Misic M, Vuletic LB, Pavlov KH, Barisic I, Kokot A, Japjec M, Blagaic AB, Tvrdeic A, Rokotov DS, Vrcic H, Staresinic M, Sebecic B, Sikiric P. BPC 157 and Standard Angiogenic Growth Factors. *Curr Pharm Des* 2018; **24**: 1972-1989 [PMID: [29998800](#) DOI: [10.2174/1381612824666180712110447](#)]
- 3 **Kang EA**, Han YM, An JM, Park YJ, Sikiric P, Kim DH, Kwon KA, Kim YJ, Yang D, Tchah H, Hahm KB. BPC157 as Potential Agent Rescuing from Cancer Cachexia. *Curr Pharm Des* 2018; **24**: 1947-1956 [PMID: [29898649](#) DOI: [10.2174/1381612824666180614082950](#)]
- 4 **Sikiric P**, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, Drmic D, Stupnisek M, Misic M, Vuletic LB, Pavlov KH, Barisic I, Kokot A, Peklic M, Strbe S, Blagaic AB, Tvrdeic A, Rokotov DS, Vrcic H, Staresinic M, Seiwerth S. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. *Curr Pharm Des* 2018; **24**: 1990-2001 [PMID: [29879879](#) DOI: [10.2174/1381612824666180608101119](#)]
- 5 **Sikiric P**, Seiwerth S, Rucman R, Drmic D, Stupnisek M, Kokot A, Sever M, Zoricic I, Zoricic Z, Batelja L, Ziger T, Luetic K, Vlaineic J, Rasic Z, Bencic ML. Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution? *Curr Pharm Des* 2017; **23**: 4012-4028 [PMID: [28228068](#) DOI: [10.2174/1381612823666170220163219](#)]
- 6 **Sikiric P**, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, Grgic T, Strbe S, Zukanovic G, Crvenkovic D, Madzarac G, Rukavina I, Sucic M, Baric M, Starcevic N, Krstonjic Z, Bencic ML, Filipic I, Rokotov DS, Vlaineic J. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. *Curr Neuropharmacol* 2016; **14**: 857-865 [PMID: [27138887](#) DOI: [10.2174/1570159x13666160502153022](#)]
- 7 **Seiwerth S**, Brcic L, Vuletic LB, Kolenc D, Aralica G, Misic M, Zenko A, Drmic D, Rucman R, Sikiric P. BPC 157 and blood vessels. *Curr Pharm Des* 2014; **20**: 1121-1125 [PMID: [23782145](#) DOI: [10.2174/13816128113199990421](#)]
- 8 **Sikiric P**, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Stupnisek M, Suran J, Barisic I, Dzidic S, Vrcic H, Sebecic B. Stable gastric pentadecapeptide BPC 157-NO-system relation. *Curr Pharm Des* 2014; **20**: 1126-1135 [PMID: [23755725](#) DOI: [10.2174/13816128113190990411](#)]
- 9 **Sikiric P**, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Safic H, Suran J, Rak D, Dzidic S, Vrcic H, Sebecic B. Toxicity by NSAIDs. *Curr Pharm Des* 2013; **19**: 76-83 [PMID: [22950504](#) DOI: [10.2174/1381612811306010076](#)]
- 10 **Sikiric P**, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Stambolija V, Zoricic Z, Vrcic H, Sebecic B. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. *Curr Med Chem* 2012; **19**: 126-132 [PMID: [22300085](#) DOI: [10.2174/092986712803414015](#)]
- 11 **Sikiric P**, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Vrcic H, Sebecic B. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. *Curr Pharm Des* 2011; **17**: 1612-1632 [PMID: [21548867](#) DOI: [10.2174/138161211796196954](#)]
- 12 **Sikiric P**, Seiwerth S, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. *Curr Pharm Des* 2010; **16**: 1224-1234 [PMID: [20166993](#) DOI: [10.2174/138161210790945977](#)]
- 13 **Vukojevic J**, Siroglavic M, Kašnik K, Kralj T, Stančić D, Kokot A, Kolaric D, Drmic D, Sever AZ, Barišić I, Šuran J, Bojić D, Patrlj MH, Sjekavica I, Pavlov KH, Vidović T, Vlaineic J, Stupnišek M, Seiwerth S, Sikiric P. Rat inferior caval vein (ICV) ligation and particular new insights with the stable gastric pentadecapeptide BPC 157. *Vascul Pharmacol* 2018; **106**: 54-66 [PMID: [29510201](#) DOI: [10.1016/j.vph.2018.02.010](#)]
- 14 **Duzel A**, Vlaineic J, Antunovic M, Malekinusic D, Vrdoljak B, Samara M, Gojkovic S, Krezic I, Vidovic T, Bilic Z, Knezevic M, Sever M, Lojo N, Kokot A, Kolovrat M, Drmic D, Vukojevic J, Kralj T, Kasnik K, Siroglavic M, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights. *World J Gastroenterol* 2017; **23**: 8465-8488 [PMID: [29358856](#) DOI: [10.3748/wjg.v23.i48.8465](#)]
- 15 **Drmic D**, Samara M, Vidovic T, Malekinusic D, Antunovic M, Vrdoljak B, Ruzman J, Milkovic Perisa M, Horvat Pavlov K, Jeyakumar J, Seiwerth S, Sikiric P. Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine. *World J Gastroenterol* 2018; **24**: 5462-5476 [PMID: [30622376](#) DOI: [10.3748/wjg.v24.i48.5462](#)]
- 16 **Amic F**, Drmic D, Bilic Z, Krezic I, Zizek H, Peklic M, Klicek R, Pajtak A, Amic E, Vidovic T, Rakic M, Milkovic Perisa M, Horvat Pavlov K, Kokot A, Tvrdeic A, Boban Blagaic A, Zovak M, Seiwerth S, Sikiric P. Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine. *World J Gastroenterol* 2018; **24**: 5366-5378 [PMID: [30598581](#) DOI: [10.3748/wjg.v24.i47.5366](#)]
- 17 **Sever AZ**, Sever M, Vidovic T, Lojo N, Kolenc D, Vuletic LB, Drmic D, Kokot A, Zoricic I, Coric M, Vlaineic J, Poljak L, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation. *Eur J Pharmacol* 2019; **847**: 130-142 [PMID: [30690000](#) DOI: [10.1016/j.ejphar.2019.01.030](#)]
- 18 **Gojkovic S**, Krezic I, Vrdoljak B, Malekinusic D, Barisic I, Petrovic A, Horvat Pavlov K, Kolovrat M, Duzel A, Knezevic M, Kasnik Kovac K, Drmic D, Batelja Vuletic L, Kokot A, Boban Blagaic A, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari

- syndrome model in rats. *World J Gastrointest Pathophysiol* 2020; **11**: 1-19 [PMID: [32226643](#) DOI: [10.4291/wjgp.v11.i1.1](#)]
- 19 **Kolovrat M**, Gojkovic S, Krezic I, Malekinusic D, Vrdoljak B, Kasnik Kovac K, Kralj T, Drmic D, Barisic I, Horvat Pavlov K, Petrovic A, Duzel A, Knezevic M, Mirkovic I, Kokot A, Boban Blagaic A, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion. *World J Hepatol* 2020; **12**: 184-206 [PMID: [32547687](#) DOI: [10.4254/wjh.v12.i5.184](#)]
 - 20 **Winy M**, Grethe L, Maegel L, Jonigk D, Lippmann T, Klempnauer J, Poehner D. Impairment of the Peritoneal Surface as a Decisive Factor for Intestinal Adhesions in Intraperitoneal Onlay Mesh Surgery - Introducing a New Rat Model. *Int J Med Sci* 2016; **13**: 108-112 [PMID: [26941568](#) DOI: [10.7150/ijms.14056](#)]
 - 21 **Baric M**, Sever AZ, Vuletic LB, Rasic Z, Sever M, Drmic D, Pavelic-Turudic T, Sucic M, Vrcic H, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats. *Life Sci* 2016; **148**: 63-70 [PMID: [26872976](#) DOI: [10.1016/j.lfs.2016.02.029](#)]
 - 22 **Grgic T**, Grgic D, Drmic D, Sever AZ, Petrovic I, Sucic M, Kokot A, Klicek R, Sever M, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula. *Eur J Pharmacol* 2016; **780**: 1-7 [PMID: [26875638](#) DOI: [10.1016/j.ejphar.2016.02.038](#)]
 - 23 **Skorjanec S**, Kokot A, Drmic D, Radic B, Sever M, Klicek R, Kolenc D, Zenko A, Lovric Bencic M, Belosic Halle Z, Situm A, Zivanovic Posilovic G, Masnec S, Suran J, Aralica G, Seiwerth S, Sikiric P. Duodenocutaneous fistula in rats as a model for "wound healing-therapy" in ulcer healing: the effect of pentadecapeptide BPC 157, L-nitro-arginine methyl ester and L-arginine. *J Physiol Pharmacol* 2015; **66**: 581-590 [PMID: [26348082](#)]
 - 24 **Klicek R**, Sever M, Radic B, Drmic D, Kocman I, Zoricic I, Vuksic T, Ivica M, Barisic I, Ilic S, Berkopic L, Vrcic H, Brcic L, Blagaic AB, Coric M, Brcic I, Rokotov DS, Anic T, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocolic fistulas in rats: role of the nitric oxide-system. *J Pharmacol Sci* 2008; **108**: 7-17 [PMID: [18818478](#) DOI: [10.1254/jphs.fp0072161](#)]
 - 25 **Skorjanec S**, Dolovski Z, Kocman I, Brcic L, Blagaic Boban A, Batelja L, Coric M, Sever M, Klicek R, Berkopic L, Radic B, Drmic D, Kolenc D, Ilic S, Cesarec V, Tonkic A, Zoricic I, Mise S, Staresinic M, Ivica M, Lovric Bencic M, Anic T, Seiwerth S, Sikiric P. Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole. *Dig Dis Sci* 2009; **54**: 46-56 [PMID: [18649140](#) DOI: [10.1007/s10620-008-0332-9](#)]
 - 26 **Vuksic T**, Zoricic I, Brcic L, Sever M, Klicek R, Radic B, Cesarec V, Berkopic L, Keller N, Blagaic AB, Kokic N, Jelic I, Geber J, Anic T, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. *Surg Today* 2007; **37**: 768-777 [PMID: [17713731](#) DOI: [10.1007/s00595-006-3498-9](#)]
 - 27 **Sever M**, Klicek R, Radic B, Brcic L, Zoricic I, Drmic D, Ivica M, Barisic I, Ilic S, Berkopic L, Blagaic AB, Coric M, Kolenc D, Vrcic H, Anic T, Seiwerth S, Sikiric P. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. *Dig Dis Sci* 2009; **54**: 2070-2083 [PMID: [19093208](#) DOI: [10.1007/s10620-008-0598-y](#)]
 - 28 **Lojo N**, Rasic Z, Zenko Sever A, Kolenc D, Vukusic D, Drmic D, Zoricic I, Sever M, Seiwerth S, Sikiric P. Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats. *PLoS One* 2016; **11**: e0162590 [PMID: [27627764](#) DOI: [10.1371/journal.pone.0162590](#)]
 - 29 **Robert A**. Cytoprotection by prostaglandins. *Gastroenterology* 1979; **77**: 761-767 [PMID: [38173](#)]
 - 30 **Robert A**. Cytoprotection and prostaglandins. *Klin Wochenschr* 1986; **64** Suppl 7: 40-43 [PMID: [3560780](#)]
 - 31 **Robert A**, Nezamis JE, Lancaster C, Davis JP, Field SO, Hanchar AJ. Mild irritants prevent gastric necrosis through "adaptive cytoprotection" mediated by prostaglandins. *Am J Physiol* 1983; **245**: G113-G121 [PMID: [6869543](#) DOI: [10.1152/ajpgi.1983.245.1.G113](#)]
 - 32 **Robert A**, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats. *Gastroenterology* 1979; **77**: 433-443 [PMID: [456839](#)]
 - 33 **Szabó S**. Critical and timely review of the concept of gastric cytoprotection. *Acta Physiol Hung* 1989; **73**: 115-127 [PMID: [2688357](#)]
 - 34 **Yasukawa K**, Tokuda H, Tun X, Utsumi H, Yamada K. The detrimental effect of nitric oxide on tissue is associated with inflammatory events in the vascular endothelium and neutrophils in mice with dextran sodium sulfate-induced colitis. *Free Radic Res* 2012; **46**: 1427-1436 [PMID: [22998024](#) DOI: [10.3109/10715762.2012.732698](#)]
 - 35 **Mazuji MK**, Kalambaheti K, Pawar B. Prevention of adhesions with polyvinylpyrrolidone. *Arch Surg* 1964; **89**: 1011-1015 [PMID: [14208444](#) DOI: [10.1001/archsurg.1964.01320060079015](#)]
 - 36 **Davey AK**, Maher PJ. Surgical adhesions: a timely update, a great challenge for the future. *J Minim Invasive Gynecol* 2007; **14**: 15-22 [PMID: [17218224](#) DOI: [10.1016/j.jmig.2006.07.013](#)]
 - 37 **Collen D**. On the regulation and control of fibrinolysis. *Thromb Haemost* 1980; **43**: 77-89 [PMID: [6450468](#)]
 - 38 **Brüggemann D**, Tchartchian G, Wallwiener M, Münster K, Tinneberg HR, Hackethal A. Intra-abdominal adhesions: definition, origin, significance in surgical practice, and treatment options. *Dtsch Arztebl Int* 2010; **107**: 769-775 [PMID: [21116396](#) DOI: [10.3238/arztebl.2010.0769](#)]
 - 39 **Seiwerth S**, Sikiric P, Grabarevic Z, Zoricic I, Hanzevacki M, Ljubanovic D, Coric V, Konjevoda P, Petek M, Rucman R, Turkovic B, Perovic D, Mikus D, Jandrijevic S, Medvidovic M, Tadic T, Romac B, Kos J, Peric J, Kolega Z. BPC 157's effect on healing. *J Physiol Paris* 1997; **91**: 173-178 [PMID: [9403790](#) DOI: [10.1016/s0928-4257\(97\)89480-6](#)]
 - 40 **Mikus D**, Sikiric P, Seiwerth S, Petricevic A, Aralica G, Druzijancic N, Rucman R, Petek M, Pigac B, Perovic D, Kolombo M, Kokic N, Mikus S, Duplancic B, Fattorini I, Turkovic B, Rotkvic I, Mise S, Prkacin I, Konjevoda P, Stambuk N, Anic T. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. *Burns* 2001; **27**: 817-827 [PMID: [11718984](#) DOI: [10.1016/s0305-4179\(01\)00055-9](#)]

- 41 **Sikiric P**, Seiwerth S, Mise S, Staresinic M, Bedekovic V, Zarkovic N, Borovic S, Gjurasin M, Boban-Blagaic A, Batelja L, Rucman R, Anic T. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. *Burns* 2003; **29**: 323-334 [PMID: [12781609](#) DOI: [10.1016/s0305-4179\(03\)00004-4](#)]
- 42 **Bilic M**, Bumber Z, Blagaic AB, Batelja L, Seiwerth S, Sikiric P. The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 Laser healing in mice. *Burns* 2005; **31**: 310-315 [PMID: [15774286](#) DOI: [10.1016/j.burns.2004.10.013](#)]
- 43 **Staresinic M**, Petrovic I, Novinscak T, Jukic I, Pevec D, Suknaic S, Kokic N, Batelja L, Brcic L, Boban-Blagaic A, Zoric Z, Ivanovic D, Ajduk M, Sebecic B, Patrlj L, Sosa T, Buljat G, Anic T, Seiwerth S, Sikiric P. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. *J Orthop Res* 2006; **24**: 1109-1117 [PMID: [16609979](#) DOI: [10.1002/jor.20089](#)]
- 44 **Pevec D**, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. *Med Sci Monit* 2010; **16**: BR81-BR88 [PMID: [20190676](#)]
- 45 **Novinscak T**, Brcic L, Staresinic M, Jukic I, Radic B, Pevec D, Mise S, Tomasovic S, Brcic I, Banic T, Jakir A, Buljat G, Anic T, Zoricic I, Romic Z, Seiwerth S, Sikiric P. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. *Surg Today* 2008; **38**: 716-725 [PMID: [18668315](#) DOI: [10.1007/s00595-007-3706-2](#)]
- 46 **Brcic L**, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. *J Physiol Pharmacol* 2009; **60** Suppl 7: 191-196 [PMID: [20388964](#)]
- 47 **Staresinic M**, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, Aralica G, Zarkovic N, Borovic S, Srdjak M, Hajdarevic K, Kopljari M, Batelja L, Boban-Blagaic A, Turcic I, Anic T, Seiwerth S, Sikiric P. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and *in vitro* stimulates tendocytes growth. *J Orthop Res* 2003; **21**: 976-983 [PMID: [14554208](#) DOI: [10.1016/S0736-0266\(03\)00110-4](#)]
- 48 **Krivic A**, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. *J Orthop Res* 2006; **24**: 982-989 [PMID: [16583442](#) DOI: [10.1002/jor.20096](#)]
- 49 **Krivic A**, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. *Inflamm Res* 2008; **57**: 205-210 [PMID: [18594781](#) DOI: [10.1007/s00011-007-7056-8](#)]
- 50 **Cerovecki T**, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. *J Orthop Res* 2010; **28**: 1155-1161 [PMID: [20225319](#) DOI: [10.1002/jor.21107](#)]
- 51 **Sebecic B**, Nikolic V, Sikiric P, Seiwerth S, Sosa T, Patrlj L, Grabarevic Z, Rucman R, Petek M, Konjevoda P, Jadrijevic S, Perovic D, Slaj M. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. *Bone* 1999; **24**: 195-202 [PMID: [10071911](#) DOI: [10.1016/s8756-3282\(98\)00180-x](#)]
- 52 **Drmic D**, Kolenc D, Ilic S, Bauk L, Sever M, Zenko Sever A, Luetic K, Suran J, Seiwerth S, Sikiric P. Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME. *World J Gastroenterol* 2017; **23**: 5304-5312 [PMID: [28839430](#) DOI: [10.3748/wjg.v23.i29.5304](#)]
- 53 **Djakovic Z**, Djakovic I, Cesarec V, Madzarac G, Becejac T, Zukanovic G, Drmic D, Batelja L, Zenko Sever A, Kolenc D, Pajtak A, Knez N, Japjec M, Luetic K, Stancic-Rokotov D, Seiwerth S, Sikiric P. Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME. *World J Gastroenterol* 2016; **22**: 9127-9140 [PMID: [27895400](#) DOI: [10.3748/wjg.v22.i41.9127](#)]
- 54 **Klicek R**, Kolenc D, Suran J, Drmic D, Brcic L, Aralica G, Sever M, Holjevac J, Radic B, Turudic T, Kokot A, Patrlj L, Rucman R, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. *J Physiol Pharmacol* 2013; **64**: 597-612 [PMID: [24304574](#)]
- 55 **Masneec S**, Kokot A, Zlatar M, Kalauz M, Kunjko K, Radic B, Klicek R, Drmic D, Lazic R, Brcic L, Radic R, Ivekovic R, Seiwerth S, Sikiric P. Perforating corneal injury in rat and pentadecapeptide BPC 157. *Exp Eye Res* 2015; **136**: 9-15 [PMID: [25912999](#) DOI: [10.1016/j.exer.2015.04.016](#)]
- 56 **Cesarec V**, Becejac T, Misic M, Djakovic Z, Olujic D, Drmic D, Brcic L, Rokotov DS, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy. *Eur J Pharmacol* 2013; **701**: 203-212 [PMID: [23220707](#) DOI: [10.1016/j.ejphar.2012.11.055](#)]
- 57 **Fortin CN**, Saed GM, Diamond MP. Predisposing factors to post-operative adhesion development. *Hum Reprod Update* 2015; **21**: 536-551 [PMID: [25935859](#) DOI: [10.1093/humupd/dmv021](#)]
- 58 **Hrelec M**, Klicek R, Brcic L, Brcic I, Cvjetko I, Seiwerth S, Sikiric P. Abdominal aorta anastomosis in rats and stable gastric pentadecapeptide BPC 157, prophylaxis and therapy. *J Physiol Pharmacol* 2009; **60** Suppl 7: 161-165 [PMID: [20388960](#)]
- 59 **Stupnisek M**, Franjic S, Drmic D, Hrelec M, Kolenc D, Radic B, Bojic D, Vcev A, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin. *Thromb Res* 2012; **129**: 652-659 [PMID: [21840572](#) DOI: [10.1016/j.thromres.2011.07.035](#)]
- 60 **Stupnisek M**, Kokot A, Drmic D, Hrelec M, Patrlj M, Zenko Sever A, Kolenc D, Radic B, Suran J, Bojic D, Vcev A, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine. *PLoS One* 2015; **10**: e0123454 [PMID: [25897838](#) DOI: [10.1371/journal.pone.0123454](#)]
- 61 **Konosic S**, Petricevic M, Ivancan V, Konosic L, Goluza E, Krtalic B, Drmic D, Stupnisek M, Seiwerth S, Sikiric P. Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot. *Oxid Med Cell Longev* 2019; **2019**: 9084643 [PMID: [31976029](#) DOI: [10.1155/2019/9084643](#)]

- 10.1155/2019/9084643]
- 62 **Sikiric P**, Separovic J, Anic T, Buljat G, Mikus D, Seiwert S, Grabarevic Z, Stancic-Rokotov D, Pigac B, Hanzevacki M, Marovic A, Rucman R, Petek M, Zoricic I, Ziger T, Aralica G, Konjevoda P, Prkacin I, Gjurasin M, Miklic P, Artukovic B, Tisljar M, Bratulic M, Mise S, Rotkvic I. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. *J Physiol Paris* 1999; **93**: 479-485 [PMID: [10672992](#) DOI: [10.1016/s0928-4257\(99\)00123-0](#)]
 - 63 **Hsieh MJ**, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. *J Mol Med (Berl)* 2017; **95**: 323-333 [PMID: [27847966](#) DOI: [10.1007/s00109-016-1488-y](#)]
 - 64 **Huang T**, Zhang K, Sun L, Xue X, Zhang C, Shu Z, Mu N, Gu J, Zhang W, Wang Y, Zhang Y, Zhang W. Body protective compound-157 enhances alkali-burn wound healing *in vivo* and promotes proliferation, migration, and angiogenesis in vitro. *Drug Des Devel Ther* 2015; **9**: 2485-2499 [PMID: [25995620](#) DOI: [10.2147/DDDT.S82030](#)]
 - 65 **Chang CH**, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. *Molecules* 2014; **19**: 19066-19077 [PMID: [25415472](#) DOI: [10.3390/molecules191119066](#)]
 - 66 **Chang CH**, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. *J Appl Physiol (1985)* 2011; **110**: 774-780 [PMID: [21030672](#) DOI: [10.1152/japplphysiol.00945.2010](#)]
 - 67 **Tkalcevic VI**, Cuzic S, Brajsa K, Mildner B, Bokulic A, Situm K, Perovic D, Glojnaric I, Parnham MJ. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. *Eur J Pharmacol* 2007; **570**: 212-221 [PMID: [17628536](#) DOI: [10.1016/j.ejphar.2007.05.072](#)]
 - 68 **Lazic R**, Gabric N, Dekaris I, Bosnar D, Boban-Blagaic A, Sikiric P. Gastric pentadecapeptide BPC 157 promotes corneal epithelial defects healing in rats. *Coll Antropol* 2005; **29**: 321-325 [PMID: [16117343](#)]
 - 69 **Radelj S**, Seiwert S, Sikiric P. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. *Melanoma Res* 2004; **14**: 14-15 [DOI: [10.1097/00008390-200408000-00050](#)]
 - 70 **Park JM**, Lee HJ, Sikiric P, Hahm KB. BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. *Curr Pharm Des* 2020; **26**: 2971-2981 [PMID: [32445447](#) DOI: [10.2174/1381612826666200523180301](#)]
 - 71 **Sakari T**, Christersson M, Karlbohm U. Mechanisms of adhesive small bowel obstruction and outcome of surgery; a population-based study. *BMC Surg* 2020; **20**: 62 [PMID: [32252752](#) DOI: [10.1186/s12893-020-00724-9](#)]
 - 72 **Köstenbauer J**, Truskett PG. Current management of adhesive small bowel obstruction. *ANZ J Surg* 2018; **88**: 1117-1122 [PMID: [29756678](#) DOI: [10.1111/ans.14556](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

